Inactive Instrument

LAM IND Stock Other OTC

US51280R1041

Biotechnology & Medical Research

End-of-day quote Other OTC Other stock markets
- ^USD	-

21-12-22	Parallel Industries Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2021	CI
19-09-26	Easton Pharmaceuticals Inc. cancelled the acquisition of Boutique Hotel and Real Estate Asset in the Heart of Toronto, Ontario, Canada.	CI

Parallel Industries Inc., formerly Easton Pharmaceuticals, Inc., is a development-stage company engaged in various pharmaceutical sectors and other industries. The Company has a transdermal delivery technology (Viorra Delivery Matrix or VDM), which is incorporated in a line of therapeutic over-the-counter (OTC) products. The Company owns topically-delivered drugs and therapeutic/cosmetic healthcare products focused on cancer and other health problems geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions. The Company's products are in various stages of commercialization. The Company's products include Nauseasol, which is a motion sickness gel; Skin Renou HA, which is an anti-aging wrinkle cream; Kenestrin Gel, which is a pain relief gel; Viorra, which serves as an aid to the relief of female sexual arousal disorder (FSAD); XILIVE, which is an early-stage cancer drug, and FSAD) drug, which includes a water-based complex polymer matrix.

Employees

Sector

Biotechnology & Medical Research

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	269K 236K 219K 201K 379K 25.96M 384K 2.61M 1.02M 12.7M 1.01M 988K 43.87M	P/E 2019	-4.17x	P/E 2020	-4.29x
Enterprise Value	2.75M 2.41M 2.24M 2.06M 3.88M 266M 3.93M 26.66M 10.44M 130M 10.33M 10.11M 449M	EV / Sales 2019	6.27x	EV / Sales 2020	-
Free-Float	97.34%	Yield 2019 *	-	Yield 2020	-

21-12-22	Parallel Industries Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2021	CI
19-09-26	Easton Pharmaceuticals Inc. cancelled the acquisition of Boutique Hotel and Real Estate Asset in the Heart of Toronto, Ontario, Canada.	CI
19-06-13	Easton Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	CI
19-04-30	Easton Pharmaceuticals Inc. Moves its Corporate Head Office	CI
19-04-25	Easton Pharmaceuticals Inc. acquired Supreme Sweets Inc. from Barbara and Mario Parravano.	CI
19-03-27	Easton Pharmaceuticals Inc. Signs LOI with Licensed Producer of Cannabis to Expand its Operations and Participate in its Cannabis Edibles Division	CI
19-03-10	Easton Pharmaceuticals Inc. Commences Cannabis Edibles Division	CI
19-02-05	Easton Pharmaceuticals Inc. Announces Updates on its $2,600,000 Framing Contract to Construct 150 Homes as Well as Other Initiatives	CI
19-01-23	Easton Pharmaceuticals Inc. Announces Sales Results for the Quarter Ended September 30, 2018 and December 31, 2018	CI
19-01-11	Easton Pharmaceuticals Inc. Provides Operational Update on CAD 2,600,000 Framing Contract	CI
19-01-02	Easton Pharmaceuticals Announces Signing and Commencement of CAD 2,600,000 Framing Contract to Construct 150 Homes	CI
18-11-28	Gunpowder Capital Corp. cancelled the acquisition of iBliss Inc. from Easton Pharmaceuticals Inc..	CI
18-09-26	Easton Pharmaceuticals Inc. signed a letter of intent to acquire Boutique Hotel and Real Estate Asset in the Heart of Toronto, Ontario, Canada.	CI

21-12-29	EASTON PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q/A)	AQ
21-12-29	EASTON PHARMACEUTICALS INC. - 10-K/A - Management's Discussion and Analysis of Financial Condition and Results of Operations.	AQ
21-12-22	EASTON PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
21-12-22	EASTON PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
21-12-22	EASTON PHARMACEUTICALS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ

Manager	Title	Age	Since
Evan Karras CEO	Chief Executive Officer	-	2015-06-29
Vince Demasi COO	Chief Operating Officer	-	2018-06-19
Jose Tiran Saucedo CTO	Chief Tech/Sci/R&D Officer	-	2014-12-31

Director	Title	Age	Since
Evan Karras BRD	Director/Board Member	-	2015-06-29
Vince Demasi BRD	Director/Board Member	-	2018-06-19

LAM IND Stock Other OTC

Stocks

US51280R1041

Biotechnology & Medical Research

Valuation: LAM IND

Latest news : LAM IND

Press Releases: LAM IND

Managers and Directors: LAM IND

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-0.43%	-4.26%	+52.09%	+85.69%	55.27B
ARGENX SE	+1.08%	+2.24%	+57.01%	+60.16%	54.15B
INSMED INCORPORATED	-1.82%	-2.89%	+3.61%	+405.88%	23.11B
BIONTECH SE	-0.54%	-0.17%	-17.60%	-15.43%	23.22B
WUXI BIOLOGICS (CAYMAN) INC.	+1.03%	-0.20%	+36.49%	-3.23%	20.33B
GENMAB A/S	-1.62%	-0.34%	+29.98%	-30.07%	17.91B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.87%	-0.19%	+39.07%	+553.51%	15.76B
PHARMAESSENTIA CORPORATION	+0.43%	-10.61%	+175.63%	+299.61%	15B
EXELIXIS, INC.	-2.03%	-1.03%	+23.63%	+179.23%	13.82B
Average	-0.34%	-1.65%	+44.43%	+170.59%	26.51B
Weighted average by Cap.	-0.14%	-1.05%	+43.99%	+134.58%

	2019	2020
Net sales	1.56M 1.36M 1.27M 1.16M 2.19M 150M 2.22M 15.07M 5.9M 73.45M 5.84M 5.71M 254M	-
Net income	-323K -283K -263K -242K -455K -31.18M -462K -3.13M -1.23M -15.26M -1.21M -1.19M -52.71M	-189K -165K -153K -141K -266K -18.19M -269K -1.83M -715K -8.9M -708K -693K -30.75M
Net Debt	8.41M 7.37M 6.84M 6.29M 11.85M 812M 12.02M 81.51M 31.9M 397M 31.58M 30.89M 1.37B	2.48M 2.18M 2.02M 1.86M 3.5M 240M 3.55M 24.06M 9.42M 117M 9.32M 9.12M 405M